-INCLUSION CRITERIA:

          1. Patients with histologically proven glioblastomas or gliosarcomas that express
             epidermal growth factor receptor(EGFRv)III as assessed by immunohistochemistry (IHC)
             or polymerase chain reaction (PCR) confirmed by the National Cancer Institute (NCI)
             Laboratory of Pathology.

          2. Patients must have progression of disease after radiotherapy (including patients that
             undergo surgery for recurrent disease and are rendered no evidence of disease (NED)).
             This includes recurrent glioblastoma (GBM) after receiving all standard first-line
             treatment, including surgery (if feasible due to neurosurgical and neuro-anatomical
             considerations) and adjuvant radiotherapy +/- chemotherapy.

          3. Patients must either not be receiving steroids, or be on a stable dose of steroids for
             at least five days prior to registration.

          4. Age greater than or equal to 18 years and less than or equal to age 70 years.

          5. Ability of subject to understand and the willingness to sign a written informed
             consent document.

          6. Willing to sign a durable power of attorney.

          7. Karnofsky Performance Status (KPS) greater than or equal to 60

          8. Patients of both genders must be willing to practice birth control from the time of
             enrollment on this study and for four months after treatment.

          9. Women of child-bearing potential must have a negative pregnancy test because of the
             potentially dangerous effects of the treatment on the fetus.

         10. Serology

               -  Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental
                  treatment being evaluated in this protocol depends on an intact immune system.
                  Patients who are HIV seropositive may have decreased immune-competence and thus
                  be less responsive to the experimental treatment and more susceptible to its
                  toxicities.)

               -  Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody.
                  If hepatitis C antibody test is positive, then patients must be tested for the
                  presence of antigen by Reverse transcription polymerase chain reaction (RT-PCR)
                  and be Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) negative.

         11. Hematology

               -  White blood cell (WBC) greater than or equal to 3000/mm(3)

               -  Absolute neutrophil count (ANC) greater than or equal to 1000/mm(3) without the
                  support of filgrastim

               -  Platelet count greater than or equal to 100,000/mm(3)

               -  Hemoglobin greater than or equal to 8.0 g/dl. Subjects may be transfused to reach
                  this cut-off.

         12. Chemistry

               -  Serum Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) less than
                  or equal to 2.5 x ULN

               -  Serum creatinine less than or equal to 1.6 mg/dl

               -  Total bilirubin less than or equal to 1.5 mg/dl, except in patients with
                  Gilbert's Syndrome, who must have a total bilirubin equal to or less than 3.0
                  mg/dl.

         13. Patients must be at least 4 weeks from radiation therapy. Additionally, patients must
             be at least 6 weeks from nitrosoureas, 4 weeks from temozolomide, 3 weeks from
             procarbazine, 2 weeks from vincristine and 4 weeks from last bevacizumab
             administration. Patients must be at least 4 weeks from other cytotoxic therapies not
             listed above and 2 weeks for non-cytotoxic agents (e.g., interferon, tamoxifen)
             including investigative agents. All toxicities from prior therapies should be resolved
             to Common Terminology Criteria in Adverse Events (CTCAE) less than or equal to grade 1
             (except for toxicities such as alopecia, or vitiligo).

         14. Subject's must be co-enrolled on protocol 03-C-0277

        EXCLUSION CRITERIA:

          1. A prior history of gliadel implantation in the past six months..

          2. Women of child-bearing potential who are pregnant or breast feeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          3. Active systemic infections, requiring anti-infective treatment, coagulation disorders,
             or any other active or uncompensated major medical illnesses

          4. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          5. Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          6. History of severe immediate hypersensitivity reaction to cyclophosphamide,
             fludarabine, or aldesleukin.

          7. History of coronary revascularization or ischemic symptoms.

          8. Clinically significant hemorrhagic or ischemic stroke, including transient ischemic
             attacks and other central nervous system bleeding in the preceding 6 months that were
             not related to glioma surgery. History of prior intratumoral bleeding is not an
             exclusion criteria; patients who with history of prior intratumoral bleeding, however,
             need to undergo a non-contrast head computed tomography (CT) to exclude acute
             bleeding.

          9. Other concomitant anti-cancer therapy except corticosteroids.

         10. Any patient known to have left ventricular ejection fraction (LVEF) less than or equal
             to 45%.

         11. Documented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted
             tested in patients with:

               -  A prolonged history of cigarette smoking (greater than or equal to 20 pack-year
                  smoking history, with cessation within the past two years).

               -  Symptoms of respiratory dysfunction

         12. Patients who are receiving any other investigational agents.

         13. Documented LVEF less than or equal to 45% tested in patients:

               -  Age greater than or equal to 65 years

               -  With clinically significant atrial and/or ventricular arrhythmias including but
                  not limited to: atrial fibrillation, ventricular tachycardia, second or third
                  degree heart block or have a history of ischemic heart disease and/or chest pain.